Seneca EIS portfolio company Premaitha Health is on the verge of tapping into a multi-billion pound market with its ground breaking non-invasive prenatal screening test for pregnant women.
Chief executive of the Manchester-based company, Dr Stephen Little, said there was already strong demand for the newly-developed IONA test, which detects the risk of Downes Syndrome and other serious genetic diseases in unborn babies.
“We weren’t making money, but we were developing a product,” he said. “Now it’s there and available. We’re using it. Tests are getting done. This is only in the last couple of months, but it’s all happening now. Up until the back end of last year, we were effectively a development company. Now we are a sales and marketing company.”
See the article in full at TheBusinessDesk.com